Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2009;119:3044-3046
Published online before print June 8, 2009, doi: 10.1161/CIRCULATIONAHA.109.870006
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
119/24/3044    most recent
CIRCULATIONAHA.109.870006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by De Keulenaer, G. W.
Right arrow Articles by Brutsaert, D. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Keulenaer, G. W.
Right arrow Articles by Brutsaert, D. L.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Other heart failure
Right arrowRelated Article

(Circulation. 2009;119:3044-3046.)
© 2009 American Heart Association, Inc.


Editorial

The Heart Failure Spectrum

Time for a Phenotype-Oriented Approach

Gilles W. De Keulenaer, MD, PhD; Dirk L. Brutsaert, MD, PhD

From the Centre for Heart Failure and Cardiac Rehabilitation, Middelheim Hospital, University of Antwerp, Antwerp, Belgium.

Correspondence to Gilles De Keulenaer, MD, PhD, Universiteitsplein 1, Campus Drie Eiken, Bldg T, 2nd Floor, 2610 Wilrijk, Belgium. Email gilles.dekeulenaer@ua.ac.be


Key Words: Editorials • heart failure • ventricular ejection fraction • models, cardiovascular • risk factors


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Chronic heart failure (HF) occurs at any level of left ventricular ejection fraction (LVEF). Mostly driven by clinical trial design, HF has nevertheless been dichotomized according to LVEF as HF with preserved ejection fraction (HFPEF) or HF with reduced ejection fraction (HFREF). During the ongoing discussion on the pathophysiology of HF, some researchers have focused on differences whereas others have focused on the overlap between HFPEF and HFREF. These discussions have received great attention especially because recent clinical trials have shown an unexplained resistance to therapy (especially to renin-angiotensin-aldosterone system inhibition) in HFPEF. With no alternative therapies available, medical progress in HFPEF is stagnating.

Article see p 3070

The current issue of Circulation contains a report on clinical characteristics and risk factors in patients with incident HF among Framingham Heart Study participants.1 Incident HF was classified as either HFREF when LVEF was ≤45% or as HFPEF when LVEF was >45%. HFPEF accounted for 41% of the inclusions. Female gender, elevated systolic blood pressure, and atrial fibrillation enhanced the odds to be classified as HFPEF whereas prior myocardial infarction and left bundle branch block reduced these odds. Among preonset HF patient characteristics, only female gender increased the odds of developing HFPEF instead of HFREF. These data are largely consistent with previous surveys on patient characteristics in HF and add information to this syndrome’s phenotypic diversity.

As stated in the article, the investigators’ rationale to subdivide patient records into 2 groups, according to an a priori cutoff value of LVEF of 45%, . . . [Full Text of this Article]


Related Article:

Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute
Douglas S. Lee, Philimon Gona, Ramachandran S. Vasan, Martin G. Larson, Emelia J. Benjamin, Thomas J. Wang, Jack V. Tu, and Daniel Levy
Circulation 2009 119: 3070-3077. [Abstract] [Full Text]